Systematic Review

Effect of sodium iron ethylenediaminetetra-acetate (NaFeEDTA) on haemoglobin and serum ferritin in iron-deficient populations: a systematic review and meta-analysis of randomised and quasi-randomised controlled trials

Bo Wang, Siyan Zhan, Yinyin Xia and Liming Lee*
Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, 38 Xueyuan Road, Haidian District, Beijing 100083, China
(Received 29 October 2007 – Revised 9 May 2008 – Accepted 9 May 2008 – First published online 13 June 2008)

We aimed to synthesise evidence to assess the effect and safety of NaFeEDTA on Hb and serum ferritin in Fe-deficient populations. We performed a systematic review, identifying potential studies by searching the electronic databases of Medline, Cochrane Library, Embase, WHO Library and China National Knowledge Infrastructure. We also hand-searched relevant conference proceedings and reference lists. Finally, we contacted experts in the field. The selection criteria included randomised or quasi-randomised controlled trials of NaFeEDTA compared with placebo. Hb, serum ferritin and adverse effects were outcomes of interest. Inclusion decisions, quality assessment and data extraction were performed by two reviewers independently. Seven studies met the inclusion criteria. All included studies assessed the effect of NaFeEDTA on Hb concentration, four studies assessed the effect on serum ferritin concentration, and one study on serum Zn concentration. After the intervention, Hb concentration and serum ferritin concentration were both higher in the NaFeEDTA group compared with the control group. For Hb, data from six studies could be pooled and the pooled estimate (weighted mean difference) was 8.56 (95% CI 2.21, 14.90) g/l (P = 0.008). For serum ferritin, data from four studies could be pooled and the pooled difference was 1.58 (95% CI 1.20, 2.09) μg/l (P < 0.001). Subgroup analysis indicated that a lower baseline Hb level was associated with a greater increase in Hb concentration. No significant difference in serum Zn concentration was found. We concluded that NaFeEDTA increased both Hb concentration and serum ferritin concentration substantially in Fe-deficient populations, and could be an effective Fe preparation to combat Fe deficiency.

Sodium iron ethylenediaminetetra-acetate: Haemoglobin: Iron deficiency: Meta-analyses

Fe deficiency is one of the three biggest ‘hidden hungers’ (Fe deficiency, iodine deficiency and vitamin A deficiency) in the world. According to a report from the WHO in 2001(1), over 2 billion individuals suffer from Fe-deficiency anaemia (IDA). The epidemic situation of Fe deficiency is more severe in developing countries. In 2002, the National Nutrition and Health Survey revealed that the average anaemia prevalence in China was 15.2% and for children below the age of 2 years, individuals older than the age of 60 years and child-bearing women, the corresponding prevalence was 24.2, 21.5 and 20.6%, respectively(2). The WHO ranked Fe deficiency as the seventh most important preventable risk factor for diseases, disability and death in 2002(3).

Fe is an essential element for Hb synthesis in the human body. Fe deficiency can lead to a reduction in Hb synthesis and damaged health in individuals. The impact of IDA on health manifests in the following aspects(4–9). IDA could lead to low birth weight, increased mother and neonatal mortality, and increased infant mortality. In infancy, IDA will delay physical and mental development and thus damage the work capacity in adulthood. In children, IDA will increase the chances and prolong the duration of upper respiratory tract infections. As anaemia damages capacity related to O2 transporting and lowers tolerance, the physical strength and work capacity of all IDA individuals will be harmed and undoubtedly this will lead to decreased income on an individual, family and country level. The reduction in economic productivity caused by anaemia was estimated to be 326 billion Yuan in China in 2001, which accounted for 3.6% of gross domestic product(10).

Abbreviations: EPOC, Effective Practice and Organisation of Care Group; IDA, Fe-deficiency anaemia.
* Corresponding author: Professor Liming Lee, fax +86 10 82801528 extension 335, email lmlee@vip.163

doi:10.1017/S0007114508012208
reason why Fe deficiency is epidemic in most developing countries is that a cereal-based diet is rich in phytic acid which decreases the bioavailability of Fe\(^{12-14}\). When using most Fe salts for controlling Fe deficiency, the influence of factors that could inhibit the bioavailability of Fe can hardly be avoided. As an Fe-fortification compound, NaFeEDTA has a high Fe bioavailability in the human body through protection against inhibition by phytic acid\(^{15}\). Experiments have shown that the bioavailability of Fe in NaFeEDTA is two to three times higher than the traditional Fe preparation, FeSO\(_4\) (ferrous sulfate), which is generally regarded as having a relatively high bioavailability of Fe compared with other Fe preparations\(^{15,16}\). On the other hand, NaFeEDTA could promote the absorption of non-haem Fe in the diet\(^{17}\). Consequently, it has the potential to be effective against Fe deficiency. To date, the effect and safety of NaFeEDTA for Fe deficiency have not been systematically evaluated. Our objective was to evaluate the effect and safety of NaFeEDTA on Hb and serum ferritin in Fe-deficient populations.

Methods

Inclusion and exclusion criteria

Types of studies. We included randomised and quasi-randomised controlled trials; we excluded controlled before-and-after studies, self-controlled before-and-after studies, interrupted time-series studies, cohort studies, case–control studies and cross-sectional studies.

Types of participants. Participants included were any population in which Fe deficiency was epidemic. In our systematic review, we defined ‘Fe deficiency’ as serum ferritin concentration\(< 12 \mu g/l\) according to the standard of the International Nutritional Anemia Consultative Group\(^{18}\).

Types of intervention. We included studies comparing NaFeEDTA v. placebo; we excluded studies in which vitamin C or other anti-anemic drugs were simultaneously administered; studies comparing Fe preparations other than NaFeEDTA v. placebo; studies comparing NaFeEDTA v. other Fe salts, or studies comparing an EDTA complex which does not contain Fe v. placebo.

Types of outcomes. We included studies that assessed the effect and safety of NaFeEDTA on Hb concentration and/or serum ferritin concentration. At the same time, we included any possible adverse effect outcomes.

Search strategy

We searched Medline (1950 to May 2007), Cochrane Library (issue 2, 2007), Embase (1966 to May 2007), WHO Library (WHOLIS) and China National Knowledge Infrastructure (CNKI) (1980 to 2007). We also hand-searched conference proceedings and reference lists and contacted specialists in the field. We did not appoint any limit in country, race, language or publication year.

Selection of eligible studies

First, randomised or quasi-randomised controlled trials were identified through title or abstract (if necessary). Further, based on inclusion and exclusion criteria, eligible studies were included through abstract or full text (if necessary). This was performed by two reviewers (B. W. and Y. X.) independently. Discrepancies were resolved by discussion between the two reviewers and unresolved disagreement was referred to a third reviewer (S. Z.).

Quality assessment

The Cochrane Effective Practice and Organisation of Care Group (EPOC) review group has established quality-assessment criteria for randomised or quasi-randomised controlled trials\(^{19}\). In our systematic review, we assessed the quality of included studies using the EPOC criteria. Two reviewers (B. W. and Y. X.) independently assessed the quality. Disagreements were resolved by discussion and by seeking the opinion of a third reviewer (S. Z.).

Data extraction

Data were extracted independently by two reviewers (B. W. and Y. X.). Any differences of opinion were resolved by discussion and consensus reached by discussion with a third reviewer (S. Z.). We collected information about methodological characteristics (study design, blinding, follow-up, allocation concealment, protection against contamination, baseline comparability, levels of allocation and analysis) and study characteristics (intervention measures, control measures, location and setting, inclusion criteria, interested outcomes, main results).

Analysis

We used RevMan software (version 4.2.8; Update Software Ltd, Oxford, Oxon, UK) to undertake heterogeneity tests and meta-analysis. As cluster randomised controlled trials were included, we used the generic inverse variance method and chose weighted mean difference as the effect measure. We decided whether to use the fixed effects model or the random effects model based on the result of the heterogeneity test. For serum ferritin outcome (the data were often log-normally distributed), we undertook meta-analysis on the logarithmic scale and report results on the arithmetic scale\(^{20}\). For one study with more than one intervention group, we divided the control group evenly according to the number of intervention groups\(^{21}\). We examined publication bias using the ‘metabias’ command in Stata 9.0 software (StataCorp LP, College Station, TX, USA).

For cluster randomised controlled trials with unit of analysis error, we computed effective sample size using the design effect, then we obtained approximately adjusted effect estimates and standard errors\(^{22}\). Intraclass correlation coefficients needed to calculate design effects were provided by one similar study. Meanwhile, we undertook sensitivity analysis for this approximate adjustment. We used final values rather than change values to undertake meta-analysis. In quality assessment, if more than three items in one study were regarded as ‘not done’, then we defined this study as ‘unacceptable’ in methodological quality, and it was not included in the analysis. For Hb outcome, we undertook subgroup analysis according to baseline Hb concentration (<120 g/l or ≥120 g/l) and intervention dose (<10 mg Fe/d...
or $\geq 10$ mg Fe/d to explore the contribution of these two variables to heterogeneity in Hb outcome.

**Results**

**Characteristics of included studies**

Fig. 1 shows the selection of eligible studies. Through comprehensive searching we found 599 articles. Among them, 145 articles that were randomised or quasi-randomised controlled trials were identified. Further, according to the inclusion and exclusion criteria, we excluded 120 articles from 145 articles. Then we identified and excluded eighteen repeated articles and finally seven studies were included (22–28).

Important excluded studies included: one study that compared the combination of NaFeEDTA and Chinese herb v. Chinese herb alone (29), two self-controlled before-and-after studies that assessed the effect of NaFeEDTA for Fe deficiency in infants and children respectively (30–32), five controlled before-and-after studies that assessed the effect of NaFeEDTA for Fe deficiency (33–38), one study that assessed the effect of NaFeEDTA on the prevention of Fe deficiency in pregnant women (39), one study that compared the effect of the combination of NaFeEDTA and vitamin C v. placebo for anaemia (40), and one study that compared the effect of NaFeEDTA v. other Fe preparations (FeSO₄, elemental Fe) for Fe deficiency (41).

Table 1 (22–28) shows the characteristics of the seven included studies. All studies were implemented in developing countries: four studies in China, two studies in Vietnam and one study in South Africa. Eligible studies included two individual randomised controlled trials and five cluster randomised controlled trials. The participants of included studies were all from Fe-deficient populations: two studies focusing on the general population, three studies focusing on children and the other two studies on women of child-bearing age. In terms of intervention forms, five studies used NaFeEDTA-fortified condiments (soya sauce, fish sauce and curry powder) while the other two studies used tablets that contained NaFeEDTA. The intervention dose of Fe from NaFeEDTA ranged from 4·9 to 20·0 mg/d; less than 10·00 mg/d in six intervention arms and more than 10·00 mg/d (including 10·00 mg/d) in two arms. Intervention duration ranged from 3 to 24 months. All studies reported Hb concentration and four studies reported serum ferritin concentration. Only one study reported serum Zn concentration as a possible adverse effect outcome.

**Methodological quality of included studies**

According to the EPOC checklist (19), we assessed the quality of the included studies in six aspects: allocation concealment, follow-up, baseline measurement, blinded assessment of outcomes, reliable outcome measure and protection against contamination. All controlled trials had adequate follow-up, good comparability in baseline measurement between intervention and control groups, blinded assessment of outcome, reliable outcome measures and measures to protect against contamination. Allocation concealment was implemented in four studies (22, 24, 25, 27), not clear in two studies (26, 28) and...
<table>
<thead>
<tr>
<th>Study</th>
<th>Location</th>
<th>Design</th>
<th>Age group</th>
<th>Sample size</th>
<th>Eligibility and exclusion criteria</th>
<th>Baseline measurements of Fe status*</th>
<th>NaFeEDTA fortification or supplementation</th>
<th>Fe status after the intervention*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ballot et al.</td>
<td>South Africa</td>
<td>Cluster RCT</td>
<td>≥ 10 years</td>
<td>T, n 984</td>
<td>Indian volunteers recruited from a subeconomic housing area</td>
<td>Hb (g/l)</td>
<td>Fe dose, 7·7 mg/d; form of intervention, fortified Fe; duration of fortification, 2 years; duration of observation, 2 years</td>
<td>Hb (g/l)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Fe, n 503 Exclusion: children aged &lt; 10 years; individuals with Hb ≤ 90 g/l</td>
<td>Fe, 134·7 (18·7)</td>
<td></td>
<td>Fe, 141·3 (16·8)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pl, n 481</td>
<td>Pl, 137·4 (18·6)</td>
<td>SF (µg/l)</td>
<td>Pl, 139·9 (17·2)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>SF, 18·2 (5·0–66·0)</td>
<td>SF, 37·2 (12·6–109·6)</td>
<td>Pl, 26·3 (8·1–85·1)</td>
</tr>
<tr>
<td>Huo et al.</td>
<td>China</td>
<td>Individual RCT</td>
<td>11–17 years</td>
<td>T, n 304</td>
<td>All Fe-deficient anaemic schoolchildren from three selected middle schools</td>
<td>Hb (g/l)</td>
<td>Fe dose, 5·0, 20·0 mg/d; form of intervention, fortified Fe; duration of fortification, 3 months; duration of observation, 3 months</td>
<td>Hb (g/l)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Fe1, n 100</td>
<td>Fe1, 116·1 (5·1)</td>
<td></td>
<td>Fe1, 140·0 (9·5)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Fe2, n 102</td>
<td>Fe2, 115·4 (5·1)</td>
<td></td>
<td>Fe2, 135·7 (8·5)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pl, n 102</td>
<td>Pl, 116·9 (5·5)</td>
<td></td>
<td>Pl, 118·5 (4·7)</td>
</tr>
<tr>
<td>Wang et al.</td>
<td>China</td>
<td>Cluster RCT</td>
<td>7–11 years</td>
<td>T, n 343</td>
<td>All children from one selected primary school</td>
<td>Hb (g/l)</td>
<td>Fe dose, 5·0 mg/d; form of intervention, Fe tablet; duration of fortification, 3 months; duration of observation, 3 months</td>
<td>Hb (g/l)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Fe, n 178</td>
<td>Fe, 125·9 (8·9)</td>
<td></td>
<td>Fe, 132·5 (9·4)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pl, n 165</td>
<td>Pl, 124·1 (8·5)</td>
<td></td>
<td>Pl, 125·9 (8·1)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>T, n 162</td>
<td>Hb (g/l)</td>
<td></td>
<td>Hb (g/l)</td>
</tr>
<tr>
<td>Wang et al.</td>
<td>China</td>
<td>Cluster RCT</td>
<td>&lt; 6 years</td>
<td>T, n 162</td>
<td>All preschool children from three selected villages</td>
<td>Hb (g/l)</td>
<td>Fe dose, 5·0 mg/d; form of intervention, Fe tablet; duration of fortification, 3 months; duration of observation, 3 months</td>
<td>Hb (g/l)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Fe, n 178</td>
<td>Fe, 115·3 (11·4)</td>
<td></td>
<td>Fe, 120·9 (9·4)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pl, n 165</td>
<td>Pl, 115·4 (10·9)</td>
<td></td>
<td>Pl, 116·3 (10·1)</td>
</tr>
<tr>
<td>Thuy et al.</td>
<td>Vietnam</td>
<td>Individual RCT</td>
<td>17–49 years</td>
<td>T, n 152</td>
<td>Women who were aged 17–49 years, were employed in one of the six selected factories, and had Hb &gt; 80 but &lt; 120 g/l</td>
<td>Hb (g/l)</td>
<td>Fe dose, 10·0 mg/d; form of intervention, fortified Fe; duration of fortification, 6 months; duration of observation, 6 months</td>
<td>Hb (g/l)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Fe, n 76</td>
<td>Fe, 110·7 (8·0)</td>
<td></td>
<td>Fe, 116·3 (8·7)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pl, n 76</td>
<td>Pl, 110·4 (8·7)</td>
<td>SF (µg/l)</td>
<td>Pl, 107·6 (11·0)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>SF, 13·6 (10·1–18·2)</td>
<td>SF, 30·9 (23·4–40·6)</td>
<td>Pl, 14·6 (11·3–19·0)</td>
</tr>
<tr>
<td>Chen et al.</td>
<td>China</td>
<td>Cluster RCT</td>
<td>≥ 3 years</td>
<td>T, n 4479</td>
<td>All residents of nine selected villages</td>
<td>Hb (g/l)</td>
<td>Fe dose, 4·9 mg/d; form of intervention, fortified Fe; duration of fortification, 18 months; duration of observation, 18 months</td>
<td>Hb (g/l)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Fe, n 2344</td>
<td>Fe, 121·0 (13·2)</td>
<td></td>
<td>Fe, 130·2 (12·6)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pl, n 2135</td>
<td>Pl, 122·6 (12·3)</td>
<td></td>
<td>Pl, 126·5 (12·0)</td>
</tr>
<tr>
<td>Study</td>
<td>Location</td>
<td>Design</td>
<td>Age group</td>
<td>Sample size</td>
<td>Eligibility and exclusion criteria</td>
<td>Baseline measurements of Fe status*</td>
<td>NaFeEDTA fortification or supplementation</td>
<td>Fe status after the intervention*</td>
</tr>
<tr>
<td>---------------------</td>
<td>----------</td>
<td>-------------------</td>
<td>-----------------</td>
<td>-------------</td>
<td>-----------------------------------------------------------------------------------------------------</td>
<td>-----------------------------------</td>
<td>----------------------------------------------------------------------------------------------------------------</td>
<td>----------------------------------</td>
</tr>
<tr>
<td>Thuy et al. 2005(26)</td>
<td>Vietnam</td>
<td>Cluster RCT</td>
<td>16–49 years</td>
<td>T, n 576</td>
<td>Women from twenty-one selected villages who were aged 16–49 years</td>
<td>SF (µg/l) Fe, 4·3 (1·9–9·8) Pl, 4·7 (2·2–10·0)</td>
<td>Fe dose, 9·0 mg/d; form of intervention, fortified Fe; duration of fortification, 18 months; duration of observation, 18 months</td>
<td>SF (µg/l) Fe, 6·9 (2·8–17·4) Pl, 5·8 (2·0–16·2)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Fe, n 288</td>
<td>Exclusion: pregnant women</td>
<td>Hb (g/l) Fe, 125·6 (10·4) Pl, 126·3 (10·8)</td>
<td>Fe, 131·1 (11·5)</td>
<td>Hb (g/l) Fe, 125·6 (10·4) Pl, 126·3 (10·8)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pl, n 288</td>
<td></td>
<td>SF (µg/l) Fe, 29·8 (6·2–141·3) Pl, 25·3 (4·8–138·0)</td>
<td>Pl, 128·6 (12·3)</td>
<td>Pl, 6·1 (12·6–346·7) Pl, 26·6 (4·1–169·8)</td>
</tr>
</tbody>
</table>

RCT, randomised controlled trial; T, total sample size; Pl, placebo; SF, serum ferritin.
* Mean (SD) for Hb values; geometric mean (SD range) for SF values.
† This study had two intervention arms, a high-dose arm and a low-dose arm. The high-dose arm provided an Fe dose of 20 mg/d and the low-dose arm, 5 mg/d.
randomised trials with unit of analysis error (weighted mean difference 2.29 (95 % CI 1.62, 3.16) mg/l (P<0.001).

Possible adverse effects. One study reported the effect of NaFeEDTA on serum Zn concentration; there was no difference (mean difference 0.1 (95 % CI 2.1, 1.8) mmol/l; P=0.910; power 90.0 %) in serum Zn concentration between the intervention group and control group. No other possible adverse effect was reported.

Discussion

Inclusion and exclusion criteria

Besides Hb, we added serum ferritin as an outcome addressed in our systematic review. Serum ferritin was found to be more sensitive than Hb when measuring change in the status of Fe(43,44). Research has shown that serum ferritin at 1 mg/l represents 8.0–10.0 mg body Fe stores(45–47). One latest systematic review also indicated the importance of this outcome(48).

Methods of review

In terms of quality assessment, scales with multiple items and complex scoring systems were not supported by empirical evidence(49). In our systematic review, we used quality-assessment criteria (including six items) established by the Cochrane EPOC review group based on threats to validity of studies(19). The criteria did not provide cut-points to define high-quality studies or low-quality studies. Considering that restriction to high-quality studies may exclude much information, while inclusion of low-quality studies may bias the summary effect estimate, we defined studies in which more than three items were regarded as ‘not done’ as ‘unacceptable’ in methodological quality and we did not include such studies in our analysis.

For continuous outcomes, usually analysis based on ‘change values’ is more efficient and powerful than comparison of final values as it removes a component of between-individual variability from the analysis(20). In our systematic review, all included studies only reported ‘final values’ and we could not compute SD for change value measurements because SE, t value or p value was not provided. However, no substantial difference between groups in baseline measurements in each included study meant that the difference in mean final values would on average be the same as difference in mean change values. Thus comparison of change values could be assumed to be addressing exactly the same underlying effects as analysis based on final values(20). So we used final values to undertake the meta-analysis and did not impute standard deviation of change values using correlation coefficient between the pre-test and post-test variance.

Unit of analysis error, which is caused by ignoring cluster design effect when undertaking analysis at the individual

<table>
<thead>
<tr>
<th>Study</th>
<th>WMD (g/l)</th>
<th>SE</th>
<th>WMD (random) and 95 % CI</th>
<th>Weight (%)</th>
<th>WMD (random) and 95 % CI</th>
<th>95 % CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ballot et al(22)</td>
<td>1.40</td>
<td>1.39</td>
<td>0.00000*</td>
<td>1.00</td>
<td>1.40</td>
<td>1.39</td>
</tr>
<tr>
<td>Wang et al(24)</td>
<td>6.60</td>
<td>0.99</td>
<td>N/A†</td>
<td>N/A</td>
<td>6.60</td>
<td>N/A</td>
</tr>
<tr>
<td>Wang et al(25)</td>
<td>4.60</td>
<td>1.60</td>
<td>0.02723‡</td>
<td>2.44</td>
<td>4.60</td>
<td>2.49</td>
</tr>
<tr>
<td>Chen et al(27)</td>
<td>3.70</td>
<td>0.39</td>
<td>0.02723‡</td>
<td>13.14</td>
<td>3.70</td>
<td>1.40</td>
</tr>
<tr>
<td>Serum ferritin (log mg/l)§</td>
<td>0.15</td>
<td>0.04</td>
<td>0.05041*</td>
<td>1.15</td>
<td>0.15</td>
<td>0.04</td>
</tr>
<tr>
<td>Chen et al(27)</td>
<td>0.08</td>
<td>0.02</td>
<td>0.01393‡</td>
<td>6.13</td>
<td>0.08</td>
<td>0.04</td>
</tr>
</tbody>
</table>

ICCs, intracluster correlation coefficient; N/A, not available.

* Here we used ICC of Hb and serum ferritin at the family level provided by the Health Survey for England 1994.

† Here we used ICC of Hb at the class level from external sources; meanwhile this study did not provide information on the number of clusters. Thus, approximate adjustment analysis could not be done.

‡ Here we used ICC of Hb and serum ferritin at the postcode sector level provided by the Health Survey for England 1994.

§ For serum ferritin, the estimates and se are shown on the logarithmic scale.

Table 2. Results of original analysis and approximate adjustment analysis of cluster randomised controlled trials with unit of analysis error

Fig. 2. Forest plot for weighted mean difference (WMD) in Hb (g/l) with NaFeEDTA (seven analytic components).
level, existed in many cluster randomised controlled trials\(^{50-55}\). This mistake always leads to false positives, which Cornfield called a self-deceiving action\(^{56}\). In a meta-analysis, cluster randomised controlled trials with unit of analysis error would have more narrow CI and thus would be given bigger weight mistakenly. In our systematic review, we performed approximate adjustment analysis for those trials with this kind of error (also we undertook sensitivity analysis for this adjustment).

Investigation of sources of heterogeneity will increase both the scientific and the clinical relevance of the results of meta-analyses\(^{57}\). Subgroup analysis and meta-regression are usual methods to explore heterogeneity of effect. It is very unlikely that meta-regression will produce useful findings unless there are at least ten studies\(^{20}\). In our systematic review, we only undertook subgroup analysis in Hb outcome, as the number of studies included was less than ten. It has been suggested that the number of investigated variables should be small enough and the scientific rationale for investigating each characteristic should be ensured\(^{20}\). We selected baseline Hb and intervention dose as the investigated variables and excluded two other variables, duration of intervention and form of intervention. A previous review indicated that 2 or 3 months should be a threshold to detect an association between duration of intervention and Hb effect\(^{48}\), while the duration was at least 3 months in all the included studies of our review. For most Fe salts, the absorption from supplements (such as tablets) is significantly higher than from fortified food, as the absorption of Fe is considerably inhibited by food vehicles such as wheat, maize and rice\(^{58,59}\). On the contrary, it has been demonstrated that NaFeEDTA exchanges completely with food Fe in the lumen of the gut but with the characteristic that the absorption is higher than expected from other Fe salts used as Fe fortification\(^{60}\). This means the absorption of NaFeEDTA in the fortified form will probably not be different from the supplementation form, and thus different forms of intervention will not contribute to heterogeneity. For serum ferritin outcome, we did not even perform subgroup analysis, considering only four studies were included.

Funnel plots are a usual way to identify publication bias. Symmetry or asymmetry is generally defined through visual examination while visual interpretation may vary between observers\(^{61}\). In our systematic review, we used more formal statistical methods to examine publication bias in Hb outcome\(^{62,63}\). For serum ferritin outcome, we did not undertake statistical testing because there is limited power to detect bias when the number of studies is small\(^{20}\).

**Results of analysis**

The results of this systematic review showed that NaFeEDTA supplementation significantly increased both the Hb concentration and serum ferritin concentration of Fe-deficient populations. The differences from the placebo group of 8·56 g/l in final Hb and 1·58 µg/l in final serum ferritin were both substantial and of significance to public health. For the two interested outcomes, sensitivity analysis, which excluded cluster randomised controlled trials with unit of analysis error, showed robustness of the results. In subgroup analysis, a significant finding was the substantially higher increase in Hb values among those with a baseline Hb of <120·00 g/l, which was supported by the evidence that lower Fe status could enhance Fe absorption\(^{64,65}\). Contrary to expectation, no significant association was found between the dose of intervention and Hb response. However, it is possible that the data may have been inadequate to detect an association due to the small number of included studies.

As to safety of NaFeEDTA, neither effect on serum Zn nor other adverse effects were found in our systematic review. This was in accordance with safety assessment results (mainly based on animal and human experiments) from the Joint FAO/WHO Expert Committee on Food Additives and
US Food and Drug Administration\textsuperscript{66–68}. The two institutions claimed that below the allowable dose, NaFeEDTA could be ‘generally recognised as safe’ or ‘safe’ when used for food fortification.

\textbf{Limitations of analysis}

Five limitations merit consideration. First, allocation concealment was not performed in one included study and was not clear in two included studies. Empirical evidence has shown that this is associated with bias\textsuperscript{69}. However, sensitivity analysis which excluded these three studies suggested that this bias was unlikely to materially to heterogeneity among included studies. However, we believe it was appropriate to combine data from heterogeneous studies in random-effect meta-analyses in our review because each study addressed the effect of NaFeEDTA on the outcomes of interest (Hb and/or serum ferritin) in Fe-deficient populations. We also undertook subgroup analyses to explore whether baseline Hb and intervention dose were significant predictors of heterogeneity in Hb outcome. Third, we used intracluster correlation coefficients from external sources (Health Survey for England 1994\textsuperscript{42}) to perform approximate adjustment analysis for cluster randomised controlled trials with unit of analysis error. While the difference between the population in England and the population in developing countries possibly affected the results of adjustment analysis, sensitivity analysis, however, demonstrated that the main results were robust. Fourth, because three included studies did not examine serum ferritin, we could only combine data from the other four studies which reported this outcome to assess the effect of NaFeEDTA on serum ferritin. Finally, two studies used tablets containing NaFeEDTA and the remainder used NaFeEDTA-fortified soya sauce, fish sauce and curry powder. Since none of the studies included cereals (wheat, maize, etc) as the vehicle for fortification, the results of our systematic review cannot be extrapolated to the use of NaFeEDTA in cereal products.

\textbf{Implication for future studies}

Effectiveness of NaFeEDTA for Fe deficiency has been validated in our systematic review. Future systematic reviews should be carried out to compare the effect of NaFeEDTA vs. other commonly used Fe preparations (such as FeSO\textsubscript{4}) for Fe deficiency.

\textbf{Conclusion}

In summary, our systematic review found that NaFeEDTA increased Hb concentration and serum ferritin concentration substantially in Fe-deficient populations. Lower baseline Hb concentration was more likely to be associated with greater Hb increase. No possible adverse effect was found. The application of NaFeEDTA will probably play an important role in controlling Fe deficiency.

\textbf{Acknowledgements}

The present study was performed at the Department of Epidemiology and Biostatistics, School of Public Health (Beijing, China).

We have not received any external support. We thank Dr Jianping Liu (Beijing University of Chinese Medicine, China) for assistance in analysis methods. B. W. applied the search strategy, performed the retrieval of articles, extracted the data from the included studies, performed the statistical analysis, and drafted the manuscript. L. L. developed the idea for the review, conceived the study design, finalised the protocol, and provided critical input for the writing of the manuscript. S. Z. provided critical input for the design of the present study, the statistical analysis, the interpretation of data, and the early versions of the manuscript. Y. X. helped with the search strategy, data extraction and statistical analysis. All of the authors took part in the discussion of the results and contributed to the drafting of the final version of the manuscript. None of the authors had any conflicts of interest.

\textbf{References}


Effect of sodium iron EDTA


